Rheumatology Grand Rounds

*Presented by*

Section of Rheumatology, Allergy & Immunology

**“Cutting Edge Therapies for the Treatment of Severe Asthma”**

Geoffrey Chupp, MD

Professor of Medicine, Yale Pulmonary, Critical Care & Sleep Medicine

**Date: Wednesday, May 5, 2021 ~ Time: 8:00-9:00 am**

ZOOM: <https://zoom.us/j/95463005582>?

Meeting ID: 954 6300 5582

CME: Text the code 20704 to 203-442-9435 from 7:45am-9:15am

**Course Director/Host: Fotios Koumpouras, MD**

***There is no corporate support for this activity***

This course will fulfill the licensure requirement set forth by the State of Connecticut

**ACCREDITATION**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**TARGET AUDIENCE**

Department faculty, attending physicians, subspecialty fellows, community physicians, resident house staff, physician assistants and medical students.

**NEEDS ASSESSMENT**

Asthma often presents with intermittent cough, wheezing, and shortness of breath brought on by triggers, relieved with bronchodilators, and diagnosis is confirmed on pulmonary function tests with variable expiratory airflow obstruction. When there are specific suspected allergic triggers involved, testing for total serum immunoglobulin E (IgE) levels and specific allergic sensitization can be pursued. For patients with asthma uncontrolled with high-dose inhaled glucocorticoids and long-acting beta-agonists (LABAs), anti-IgE therapy as well as anti- IL-14R/13R drugs can be considered. Monoclonal antibodies against IL-5 (mepolizumab) have been used for severe eosinophilic asthma. Dr. Chupp will describe the current clinical features of asthma that identify patients as candidates for biologic therapy and define the biologic pathways targeted with current therapeutics. He will also apply clinical trial data to define criteria for selection for anti-IgE, -IL-5, and IL-14R/13R drugs.

**LEARNING OBJECTIVES**

At the conclusion of this activity, participants will be able to:

* Describe the current clinical features of asthma that identify patients as candidates for biologic therapy
* Define the biologic pathways targeted with current therapeutics and discriminate specific targets of individual biologics
* Apply clinical trial data to define criteria for selction for anti-IgE, -IL-5, and IL-14R/13R drugs

**DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY DISCLOSURES**

*Speaker:* Geoffrey Chupp, MD – Astra Zeneca, GSK, Genentech, Teva, Regeneron, Sanolfi-genzyme, Amgen (Honoraria)

*Course Director:* Fotios Koumpouras, MD- Celgene (honorarium), Aurora (research grant), EMD, ULB, GSK (research grant)

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.